SCHEMBL3269145

SCHEMBL3269145

NC(=O)COC(=O)NCC1CCN(c2ncccc2-c2ccc(F)cc2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.46
HTR1A P08908 2/20 0.43
DRD2 P14416 2/20 0.43
HTR7 P34969 2/20 0.43
HTR6 P50406 2/20 0.43
CHRM3 P20309 5/20 0.42
GRIN2B Q13224 1/20 0.41
CKS1B P61024 1/20 0.41
SKP1 P63208 1/20 0.41
SKP2 Q13309 1/20 0.41
LDHA P00338 1/20 0.40
AOC3 Q16853 1/20 0.38
QPCT Q16769 1/20 0.37
QPCTL Q9NXS2 1/20 0.37
KDM4E B2RXH2 1/20 0.37
RECQL P46063 1/20 0.37
F10 P00742 1/20 0.37
RBP4 P02753 1/20 0.37
TTR P02766 1/20 0.37
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3265694 0.92 P2RX7 (0.47) P2RX7HTR1ADRD2HTR7HTR6
SCHEMBL3269154 0.91 HTR1A (0.43) P2RX7HTR1ADRD2HTR7HTR6
SCHEMBL3265674 0.87 HTR1A (0.42) P2RX7HTR1ADRD2HTR7HTR6
SCHEMBL1727778 0.84 P2RX7 (0.53) P2RX7HTR1ADRD2HTR7HTR6
SCHEMBL3270076 0.82 MALT1 (0.42) P2RX7GRIN2BCKS1BSKP1SKP2
SCHEMBL3265672 0.82 CHRM4 (0.45) P2RX7HTR1ADRD2HTR7HTR6
SCHEMBL3267012 0.82 KDM4E (0.59) DRD2LDHAKDM4ERECQL
SCHEMBL3269094 0.80 CKS1B (0.47) GRIN2BCKS1BSKP1SKP2
SCHEMBL3266878 0.79 CKS1B (0.45) HTR1ADRD2HTR7CKS1BSKP1
SCHEMBL3269143 0.78 CKS1B (0.42) P2RX7HTR1ADRD2HTR7HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120004207-A1 THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES SANOFI-AVENTIS (FR) 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004207-A1 THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES CLCN2, CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 P2RX7 1286/4885HTR1A 2958/4885DRD2 1223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.